Clinical Trials Logo

BRCA-Mutated Ovarian Carcinoma clinical trials

View clinical trials related to BRCA-Mutated Ovarian Carcinoma.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT06065059 Terminated - Breast Cancer Clinical Trials

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

Start date: December 8, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this interventional clinical trial is to learn about TNG348, a ubiquitin specific peptidase 1 (USP1) inhibitor, alone and in combination with olaparib in patients with BRCA 1/2 mutant or HRD+ solid tumors. The main question[s] it aims to answer are: - to evaluate the safety and tolerability of single agent and combination therapy - to determine the recommended dose for Phase 2 of single agent and combination therapy - to determine the pharmacokinetics of TNG348 as a single agent and in combination therapy - to evaluate the initial antineoplastic activity as a single agent and in combination therapy Participants will receive study treatment until they experience an undesirable side effect, their disease progresses or until they withdraw consent.